Zimmer Biomet (NYSE:ZBH) Given New $112.00 Price Target at Barclays

Zimmer Biomet (NYSE:ZBH) had its target price reduced by equities research analysts at Barclays from $118.00 to $112.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “underweight” rating on the medical equipment provider’s stock. Barclays‘s price objective would indicate a potential upside of 10.88% from the company’s previous close.

ZBH has been the topic of several other research reports. Truist Financial upped their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday. Oppenheimer decreased their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $124.40.

Zimmer Biomet Stock Down 1.6 %

Shares of ZBH opened at $101.01 on Monday. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $107.34 and a two-hundred day moving average price of $108.08. The stock has a market cap of $20.11 billion, a price-to-earnings ratio of 22.70, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet has a 12 month low of $99.93 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 earnings per share. Equities analysts predict that Zimmer Biomet will post 8.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM LLC grew its position in shares of Zimmer Biomet by 7.4% during the 3rd quarter. CWM LLC now owns 6,966 shares of the medical equipment provider’s stock worth $752,000 after buying an additional 481 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Zimmer Biomet by 575.8% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,230 shares of the medical equipment provider’s stock worth $241,000 after acquiring an additional 1,900 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Zimmer Biomet by 3,043.1% in the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock valued at $173,000 after purchasing an additional 1,552 shares in the last quarter. Thomasville National Bank raised its holdings in Zimmer Biomet by 5.6% in the third quarter. Thomasville National Bank now owns 95,410 shares of the medical equipment provider’s stock worth $10,300,000 after purchasing an additional 5,085 shares during the period. Finally, Paladin Wealth LLC bought a new position in shares of Zimmer Biomet during the third quarter worth $538,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.